Track all markets on TradingView
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Media

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential

  • November 9, 2024
  • 7 Views

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Latest Ratings for BNTX

Date Firm Action From To
Feb 2022 HC Wainwright & Co. Maintains Buy
Feb 2022 Morgan Stanley Maintains Equal-Weight
Feb 2022 Redburn Partners Upgrades Sell Neutral

View More Analyst Ratings for BNTX

View the Latest Analyst Ratings

read more

​ 

​Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Latest Ratings for BNTX
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Redburn PartnersUpgradesSellNeutral
View More Analyst Ratings for BNTX

View the Latest Analyst Ratings

read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.